Q4 2025 Viking Therapeutics Inc Earnings Call Transcript
Key Points
- Viking Therapeutics Inc (VKTX) achieved multiple important milestones in 2025, including the initiation of the phase 3 Vanquish clinical program for obesity.
- The company completed enrollment ahead of schedule for the Vanquish 1 study and is nearing completion for Vanquish 2.
- Positive topline results were announced from the phase 2 venture oral dosing study, demonstrating significant weight loss in patients with obesity.
- A comprehensive manufacturing and supply agreement was signed with Cordon Pharma to support potential commercialization, ensuring large-scale supply capabilities.
- Viking Therapeutics Inc (VKTX) maintains a strong financial position with over $700 million in cash, supporting ongoing and future clinical trials.
- Research and development expenses significantly increased to $153.5 million in Q4 2025, primarily due to phase 3 clinical trials.
- The company reported a net loss of $157.7 million for Q4 2025, a substantial increase from the previous year.
- General and administrative expenses, although decreased, still represent a significant cost at $11.3 million for Q4 2025.
- The cash balance decreased from $903 million at the end of 2024 to $706 million at the end of 2025.
- There is uncertainty regarding the need for additional studies or data to support the phase 3 oral program, which could impact timelines and costs.
Welcome to the Viking Therapeutics 4th quarter in 4 year 2025 financial results conference call. (Operator Instructions) As a reminder, this conference call is being recorded today, February 11, 2026. I would now like to turn the call over to Vikings manager of investor relations, Ms. Stephanie Diaz. Please go ahead, Stephanie.
Hello and thank you all for participating in today's call. Joining me today is Brian Leon, Vikings President and CEO, and Greg Zanti, Vikings CFO. Before we begin, I'd like to caution that comments made during this conference call today, February 11, 2026, will contain forward-looking statements under the safe harbor provisions of the US Private Securities Litigation Reform Act of 1,995, including statements about Viking's expectations regarding its development activities, timelines, and milestones.
Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely, and reported results should
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
